We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Open-Irrigated Catheter Aids Treatment of Atrial Flutter

By HospiMedica International staff writers
Posted on 28 Mar 2016
A novel radiofrequency (RF) ablation catheter provides an elegant cooling platform for treating atrial flutter (AF), with robust handling capabilities.

The Blazer open-irrigated (OI) RF ablation catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and RF ablation of sustained or recurrent type 1 AF in adult patients. More...
Contraindications include patients with an active systemic infection; those with a mechanical prosthetic heart valve; patients unable to receive heparin or an alternative anticoagulant; patients who have vena cava embolic protection filter devices; those who are hemodynamically unstable; and those who have myxoma or an intracardiac thrombus.

The ablation catheter features bidirectional steering, predictable trackability and torqueability, fine micromovement, and high tip stability and contact. A unique feature is Total Tip cooling, a technology to cool the catheter tip consistently during the procedure, thus improving the quality of the ablation lesion. The Blazer OI ablation catheter is intended for use with the Maestro 4000 RF Controller and the MetriQ irrigation pump, and is available with a range of tip curve styles, including standard, large, extra-long, and asymmetric. The Blazer OI ablation catheter is a product of Boston Scientific (Natick, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“The Blazer open-irrigated catheter is safe and effective for the ablation of atrial flutter," said Prof. Tom McElderry, MD, section chief of electrophysiology at the University of Alabama at Birmingham (UAB; USA), who participated in the BLOCk-CTI clinical trial of the device. “This newly approved ablation tool was built on the proven Blazer platform of therapeutic catheters and facilitates excellent maneuverability, consistent cooling, and stability during procedures.”

Cardiac ablation is a procedure that is used to correct structural problems in the heart by scarring or destroying tissue that triggers an abnormal heart rhythm, especially supraventricular tachyarrhythmias such as AF, atrial fibrillation, and atrial tachycardia. The low-risk procedure takes 2–4 hours and is most often performed in an electrophysiology or a cardiac catheterization lab. It is successful in about 90% of the people who have it.

Related Links:

Boston Scientific



Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Mammography System (Analog)
MAM VENUS
New
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.